Katerina Politi

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium
    Hippokratis Kiaris
    Department of Cell Biology, Massachusetts General Hospital Center for Cancer Research, Department of Cell Biology, Harvard Medical School, 13th St, Bldg. 149, Charlestown, MA 02129, USA
    Am J Pathol 165:695-705. 2004
  2. ncbi EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
  3. ncbi Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras
    Katrina Podsypanina
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 105:5242-7. 2008
  4. ncbi A mouse plasma peptide atlas as a resource for disease proteomics
    Qing Zhang
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Genome Biol 9:R93. 2008
  5. ncbi Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Dis Model Mech 3:111-9. 2010
  6. ncbi Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 20:1496-510. 2006
  7. ncbi A mouse model of uterine leiomyosarcoma
    Katerina Politi
    Department of Genetics and Development, Columbia University, New York, New York, USA
    Am J Pathol 164:325-36. 2004
  8. ncbi Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
  9. ncbi Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
    Lucia Regales
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e810. 2007
  10. ncbi Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice
    Apostolos Klinakis
    Department of Genetics and Development, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 103:9262-7. 2006

Collaborators

Detail Information

Publications16

  1. ncbi Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium
    Hippokratis Kiaris
    Department of Cell Biology, Massachusetts General Hospital Center for Cancer Research, Department of Cell Biology, Harvard Medical School, 13th St, Bldg. 149, Charlestown, MA 02129, USA
    Am J Pathol 165:695-705. 2004
    ....
  2. ncbi EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    ..Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity...
  3. ncbi Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras
    Katrina Podsypanina
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 105:5242-7. 2008
    ..These results demonstrate that tumor viability is maintained by each gene in a combination of oncogenes and that targeted approaches will also benefit from combination therapies...
  4. ncbi A mouse plasma peptide atlas as a resource for disease proteomics
    Qing Zhang
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Genome Biol 9:R93. 2008
    ..A major finding from this study is the identification of novel isoforms and transcript variants not previously predicted from genome analysis...
  5. ncbi Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Dis Model Mech 3:111-9. 2010
    ..This preclinical mouse model, therefore, recapitulates the molecular changes responsible for resistance to TKIs in human tumors and holds promise for the discovery of additional mechanisms of drug resistance in lung cancer...
  6. ncbi Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 20:1496-510. 2006
    ..These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations...
  7. ncbi A mouse model of uterine leiomyosarcoma
    Katerina Politi
    Department of Genetics and Development, Columbia University, New York, New York, USA
    Am J Pathol 164:325-36. 2004
    ..To begin exploring aberrant signaling events in the SVER-triggered tumorigenic pathways, we analyzed the expression profile of leiomyosarcomas by DNA microarray analysis...
  8. ncbi Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
    ..We sought to improve understanding of this process in order to provide insight into mechanisms of sensitivity and/or resistance to tyrosine kinase inhibitors and to uncover new targets for therapy...
  9. ncbi Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
    Lucia Regales
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e810. 2007
    ..The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer...
  10. ncbi Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice
    Apostolos Klinakis
    Department of Genetics and Development, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 103:9262-7. 2006
    ..Consistent with this mechanistic link, Notch1 and Myc expression is positively correlated by immunostaining in 38% of examined human breast carcinomas...
  11. ncbi Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
    Jaya Sangodkar
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Invest 122:2637-51. 2012
    ....
  12. ncbi How genetically engineered mouse tumor models provide insights into human cancers
    Katerina Politi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 29:2273-81. 2011
    ..Alternatives to GEMMs, such as chemically induced or spontaneous tumor models, are not discussed in this review...
  13. ncbi 'Designer' tumors in mice
    Katerina Politi
    Department of Genetics and Development, Columbia University, New York, NY 10032, USA
    Oncogene 23:1558-65. 2004
    ....
  14. ncbi Notch in mammary gland development and breast cancer
    Katerina Politi
    Department of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Semin Cancer Biol 14:341-7. 2004
    ..Here, we review studies of mammary tumorigenesis induced by Notch in mouse and in vitro culture models providing evidence that Notch activation is a causal factor in human breast cancer...
  15. ncbi Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma
    Christos Cheretis
    Dermatologische Klinik, Klinikum Hoyerswerda Akademisches Lehrkrankenhaus an der Technischen Universität Dresden, Germany
    Am J Dermatopathol 28:410-2. 2006
    ..The role of ERp29 in the pathogenesis of the disease and its potential diagnostic value should be explored in future investigations...
  16. ncbi Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors
    George Trimis
    Department of Biological Chemistr, Aretaieion Hospital, University of Athens Medical School, Athens, Greece
    Hum Mol Genet 17:3596-600. 2008
    ..We propose that p21 regulation is intimately linked with the ability of stromal cells to affect tumor growth...